Cortexyme Announces Agreement to Acquire Novosteo

SOUTH SAN FRANCISCO, Calif. – May 10, 2022 –Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with degenerative diseases, today announced that it entered into an agreement under which the company plans to acquire Novosteo,a privately-held biotech company...

Targeted Therapeutics to Treat Rare Skeletal Diseases, Bone Cancer and Injury

Healthcare Costs for Bone Diseases Are More Than $50 Billion Annually in the U.S.

Novosteo’s mission is to revolutionize the treatment of skeletal disease via a highly innovative drug discovery platform that delivers precisely targeted therapies to the site of bone disease or injury.
Novosteo Platform

Platform

Novosteo has a precise drug-targeting platform that allows us to take small molecules, peptides or large molecules and deliver them directly to the site of disease or injury.

PAYLOAD

  • Anabolic
  • Chemotherapy
  • Radionuclide
  • Antibiotic

LINKER

  • Fixed or cleavable

TARGETING LIGAND

  • High affinity
  • High specificity
  • Biocompatible

PIPELINE

Advancing a Pipeline of Targeted Precision Skeletal Therapeutics

Novosteo’s broad pipeline is comprised of novel precision therapies leveraging its proprietary platform. Our lead program, NOV004, is focused on accelerating fracture repair and will be entering clinical studies in 2023. We are also advancing preclinical candidates across a broad range of potential therapeutic areas including general fractures, trauma, spinal fusion, rare skeletal diseases, infection and cancer.

Program
indication
discovery
preclinical
IND enabling
Early stage clinical

NOV004

Osteogenesis Imperfecta

All Fractures

Spinal Fusion

NOV160

NOV155

NOV132

NOV182

NOV227

NOV236

NOV237

Undisclosed Cancer

Undisclosed Infection

Trauma

PROGRAM 2

PROGRAM 4

PROGRAM 5

PROGRAM 3

Undisclosed Rare Disease